A recent study suggests that Brukinsa (zanubrutinib) provides better progression-free survival than other BTK inhibitors in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The study compared zanubrutinib with Calquence (acalabrutinib) and Imbruvica (ibrutinib) by adjusting data from three major Phase 3 trials—ALPINE, ELEVATE-RR, and ASCEND—to make fair comparisons.
The results showed that zanubrutinib reduced the risk of disease progression or death by 33% compared with ibrutinib and by 43% compared with acalabrutinib. It also showed a strong benefit compared with standard chemoimmunotherapy regimens such as IR or BR. In high-risk patients, including those with 17p or 11q deletions, zanubrutinib maintained its advantage, lowering the risk of progression by about 43% to 45% compared with the other BTK inhibitors.
Researchers believe zanubrutinib’s improved results may be linked to its pharmacologic properties. Like acalabrutinib, it is more selective than first-generation ibrutinib, which may reduce off-target effects. In addition, zanubrutinib maintains steady drug levels throughout the dosing interval, allowing continuous inhibition of newly formed BTK proteins. Although early trends suggest a possible overall survival benefit, the data are still immature and not yet statistically definitive. Since no direct head-to-head trial compares all three drugs together, this analysis represents the most comprehensive indirect comparison currently available.